Biomea Fusion, Inc. Financials
Financial Health Signals
Biomea Fusion, Inc. passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Biomea Fusion, Inc. generates $0.87 in operating cash flow (-$119.9M OCF vs -$138.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
This page shows Biomea Fusion, Inc. (BMEA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Biomea Fusion, Inc.'s EBITDA was -$142.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 14.2% from the prior year.
Biomea Fusion, Inc. generated -$120.3M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 20.3% from the prior year.
Biomea Fusion, Inc. reported -$138.4M in net income in fiscal year 2024. This represents a decrease of 18.1% from the prior year.
Biomea Fusion, Inc. earned $-3.83 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 11.3% from the prior year.
Biomea Fusion, Inc. held $58.3M in cash against $0 in long-term debt as of fiscal year 2024.
Biomea Fusion, Inc. had 36M shares outstanding in fiscal year 2024. This represents an increase of 1.2% from the prior year.
Biomea Fusion, Inc. invested $118.1M in research and development in fiscal year 2024. This represents an increase of 15.2% from the prior year.
Biomea Fusion, Inc. invested $362K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 89.3% from the prior year.
BMEA Income Statement
| Metric | Q3'25 | Q4'24 | Q3'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $14.4M-42.9% | $25.2M-7.4% | $27.2M-11.7% | $30.9M+21.8% | $25.3M+15.5% | $21.9M-10.1% | $24.4M+18.8% | $20.5M |
| SG&A Expenses | $4.2M-13.1% | $4.8M-28.9% | $6.8M+5.2% | $6.5M+12.0% | $5.8M+0.9% | $5.7M+1.5% | $5.6M-1.8% | $5.7M |
| Operating Income | -$20.8M+30.8% | -$30.1M+11.6% | -$34.0M+8.8% | -$37.3M-20.0% | -$31.1M-12.5% | -$27.7M+7.9% | -$30.0M-14.3% | -$26.3M |
| Interest Expense | $4.4M | N/A | $1.3M | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$16.4M+44.0% | -$29.3M+10.6% | -$32.8M+6.0% | -$34.9M-22.7% | -$28.4M-14.2% | -$24.9M+14.3% | -$29.1M-14.8% | -$25.3M |
| EPS (Diluted) | $-0.27+66.7% | $-0.81+11.0% | $-0.91+7.1% | $-0.98-22.5% | $-0.80-14.3% | $-0.70+28.6% | $-0.98-14.0% | $-0.86 |
BMEA Balance Sheet
| Metric | Q3'25 | Q4'24 | Q3'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $55.2M-31.0% | $79.9M-27.6% | $110.4M-44.8% | $199.9M-11.2% | $225.1M-9.5% | $248.7M+120.8% | $112.6M-12.9% | $129.3M |
| Current Assets | $49.4M-27.6% | $68.3M-27.0% | $93.6M-47.8% | $179.2M-11.5% | $202.5M-10.4% | $225.9M+154.1% | $88.9M-24.5% | $117.8M |
| Cash & Equivalents | $46.6M-20.0% | $58.3M-33.7% | $88.0M-50.3% | $176.9M-11.2% | $199.1M-10.7% | $222.9M+158.3% | $86.3M-22.9% | $111.9M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $39.6M+39.5% | $28.4M-17.7% | $34.4M+12.2% | $30.7M+20.5% | $25.5M+4.5% | $24.4M-17.4% | $29.5M+42.1% | $20.8M |
| Current Liabilities | $15.6M-28.2% | $21.7M-21.4% | $27.6M+20.6% | $22.9M+41.0% | $16.2M+12.9% | $14.4M-23.5% | $18.8M-1.7% | $19.1M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $15.6M-69.7% | $51.6M-32.1% | $76.0M-55.1% | $169.2M-15.2% | $199.6M-11.0% | $224.3M+169.8% | $83.1M-23.4% | $108.5M |
| Retained Earnings | -$453.7M-17.1% | -$387.3M-8.2% | -$357.9M-43.9% | -$248.8M-16.3% | -$213.9M-15.3% | -$185.5M-15.5% | -$160.6M-22.1% | -$131.6M |
BMEA Cash Flow Statement
| Metric | Q3'25 | Q4'24 | Q3'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$11.6M+61.5% | -$30.0M-19.0% | -$25.2M-10.4% | -$22.8M+4.4% | -$23.9M+7.4% | -$25.8M-7.4% | -$24.0M-19.0% | -$20.2M |
| Capital Expenditures | $0-100.0% | $82K-55.9% | $186K+2225.0% | $8K-79.5% | $39K-90.6% | $417K-85.7% | $2.9M+308.1% | $712K |
| Free Cash Flow | -$11.6M+61.6% | -$30.1M-18.4% | -$25.4M-11.2% | -$22.8M+4.6% | -$23.9M+8.7% | -$26.2M+2.7% | -$26.9M-28.9% | -$20.9M |
| Investing Cash Flow | $0+100.0% | -$82K+55.9% | -$186K-2225.0% | -$8K+79.5% | -$39K+90.6% | -$417K+76.3% | -$1.8M-150.5% | -$701K |
| Financing Cash Flow | $2.0M+376.5% | $413K+498.6% | $69K-88.9% | $622K+350.7% | $138K-99.9% | $162.8M+80913.4% | $201K-59.0% | $490K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
BMEA Financial Ratios
| Metric | Q3'25 | Q4'24 | Q3'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -29.7%+6.9pp | -36.7%-7.0pp | -29.7%-12.2pp | -17.4%-4.8pp | -12.6%-2.6pp | -10.0%+15.8pp | -25.8%-6.2pp | -19.6% |
| Current Ratio | 3.18+0.0 | 3.15-0.2 | 3.39-4.4 | 7.84-4.7 | 12.49-3.2 | 15.74+11.0 | 4.74-1.4 | 6.17 |
| Debt-to-Equity | 2.53+2.0 | 0.55+0.1 | 0.45+0.3 | 0.18+0.1 | 0.13+0.0 | 0.11-0.2 | 0.35+0.2 | 0.19 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Biomea Fusion, Inc. profitable?
No, Biomea Fusion, Inc. (BMEA) reported a net income of -$138.4M in fiscal year 2024.
What is Biomea Fusion, Inc.'s earnings per share (EPS)?
Biomea Fusion, Inc. (BMEA) reported diluted earnings per share of $-3.83 for fiscal year 2024. This represents a -11.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Biomea Fusion, Inc.'s EBITDA?
Biomea Fusion, Inc. (BMEA) had EBITDA of -$142.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Biomea Fusion, Inc.'s free cash flow?
Biomea Fusion, Inc. (BMEA) generated -$120.3M in free cash flow during fiscal year 2024. This represents a -20.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Biomea Fusion, Inc.'s operating cash flow?
Biomea Fusion, Inc. (BMEA) generated -$119.9M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Biomea Fusion, Inc.'s total assets?
Biomea Fusion, Inc. (BMEA) had $79.9M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Biomea Fusion, Inc.'s capital expenditures?
Biomea Fusion, Inc. (BMEA) invested $362K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Biomea Fusion, Inc. spend on research and development?
Biomea Fusion, Inc. (BMEA) invested $118.1M in research and development during fiscal year 2024.
How many shares does Biomea Fusion, Inc. have outstanding?
Biomea Fusion, Inc. (BMEA) had 36M shares outstanding as of fiscal year 2024.
What is Biomea Fusion, Inc.'s current ratio?
Biomea Fusion, Inc. (BMEA) had a current ratio of 3.15 as of fiscal year 2024, which is generally considered healthy.
What is Biomea Fusion, Inc.'s debt-to-equity ratio?
Biomea Fusion, Inc. (BMEA) had a debt-to-equity ratio of 0.55 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Biomea Fusion, Inc.'s return on assets (ROA)?
Biomea Fusion, Inc. (BMEA) had a return on assets of -173.2% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Biomea Fusion, Inc.'s cash runway?
Based on fiscal year 2024 data, Biomea Fusion, Inc. (BMEA) had $58.3M in cash against an annual operating cash burn of $119.9M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Biomea Fusion, Inc.'s Piotroski F-Score?
Biomea Fusion, Inc. (BMEA) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Biomea Fusion, Inc.'s earnings high quality?
Biomea Fusion, Inc. (BMEA) has an earnings quality ratio of 0.87x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.